Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials ...

After hours: November 29 at 4:59 PM EST Loading Chart for SAVA ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Deep-pocketed investors have adopted a bullish approach towards Cassava Sciences SAVA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Egypt - e-finance has signed an agreement with Cassava Technologies to explore collaboration and joint expansion opportunities across Africa, as per a statement. Cassava Technologies will bring its ...

After hours: November 29 at 4:59 p.m. EST ...